Mirati’s adagrasib spurs 41% response in pancreatic, GI tumors, scoring points where KRAS leader Amgen hasn’t gone

Mirati’s adagrasib spurs 41% response in pancreatic, GI tumors, scoring points where KRAS leader Amgen hasn’t gone
klahucik
Fri, 01/21/2022 – 11:08